GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...